share_log

金石亚药(300434.SZ):拟与关联方共同投资领业医药

Jinshi Asia Pharmaceutical (300434.SZ): Plans to jointly invest in Lingye Pharmaceutical with related parties

Gelonghui Finance ·  Dec 28, 2023 05:14

Gelonghui, December 28 | Jinshi Ya Pharmaceutical (300434.SZ) announced that the company recently signed a “Capital Increase Agreement on Hangzhou Lingye Pharmaceutical Technology Development Co., Ltd.” (“Dragon Fruit Investment”), Hangzhou Dragon Fruit Investment Management Co., Ltd. (“Dragon Fruit Investment”), and natural person Ms. Gao Yaping. The company and Ms. Gao Yaping and Dragon Fruit Investment plan to invest a total of RMB 694.885,700 to subscribe to Lingye Pharmaceutical with an additional registered capital of RMB 27.72,89.4 million. Among them, the company plans to use RMB 31,5407.25 million to subscribe to Lingye Pharmaceutical's additional registered capital of RMB 1,2616.29 million; Ms. Gao Yaping plans to use RMB 279.449.75 million to subscribe to Lingye Pharmaceutical's additional registered capital of RMB 1,1177.99 million; and Dragon Fruit Investment plans to use RMB 10 million to subscribe to Lingye Pharmaceutical's additional registered capital of 400,000 yuan. After the capital increase, the company will hold 32.4304% of Lingye Pharmaceutical's shares. Ms. Gao Yaping holds 28.7332% of Lingye Pharmaceutical's shares. 95% Equity.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment